Table 2:
Ongoing studies of targeted therapies for R/R PTCL
Kinase | Duvelisib | NCT03372057 | Recruiting | PTCL-NOS, AITL, ALCL, NKTL |
Duvelisib + romidepsin | NCT02783625 | Recruiting | PTCL, CTCL | |
Tenalisib | NCT03770000 | Active, not recruiting | TCL | |
Copanlisib + pembrolizumab | NCT02535247 | Active, not recruiting | PTCL, transformed CTCL | |
Copanlisib + gemcitabine | NCT03052933 | Active, not recruiting | PTCL, NKTL | |
Ruxolitinib | NCT01712659 | Recruiting | ATL | |
TAK-659 + venetoclax | NCT03357627 | Active, not recruiting | NHL | |
TAK-659 | NCT02000934 | Active, not recruiting | Lymphoma | |
CPI-818 | NCT03952078 | Recruiting | TCL | |
Tenalisib + romidepsin | NCT03770000 | Active, not recruiting | TCL | |
Epigenetic | Romidepsin + ixazomib | NCT03547700 | Active, not recruiting | PTCL |
Romidepsin + azacitidine + lenalidomide | NCT04447027 | Recruiting | TCL | |
Romidepsin +/− pralatrexate +/− durvalumab +/− azacitidine | NCT03161223 | Recruiting | PTCL | |
Valemetostat | NCT02732275 | Recruiting | NHL | |
Azacitidine | NCT03593018 | Recruiting | AITL | |
Other | PRT1419 | NCT04543305 | Recruiting | NHL |
AMG 397 | NCT03465540 | Recruiting | NHL | |
AZD5991 | NCT03218683 | Recruiting | NHL | |
Venetoclax | NCT03534180 | Recruiting | PTCL, transformed MF | |
Lenalidomide + brentuximab | NCT03302728 | Recruiting | CD30+ PTCL | |
Lenalidomide + durvalumab | NCT03011814 | Recruiting | PTCL |
NKTL, NK/T-cell lymphoma; CTCL, cutaneous T-cell lymphoma; FTCL, follicular T-cell lymphoma; ATL, adult T-cell leukemia/lymphoma